Infection and Microparticles may Cause Complication of Atherosclerotic Plaques

Atherosclerosis is frequently associated with diabetes, obesity, metabolic syndrome and oxidized low density lipoproteins (oxLDL). Many studies have reported association of infection with such disorders, but with controversial results. In our view, these findings have relationship with technical differences. We showed previously, presence of infectious agents inside of ruptured plaque, using immunohistochemistry and electron microscopy. More recently, we detected Electron Lucent microparticles (ELMP) and Mycoplasma pneumoniae (Mp) lipoproteins in vulnerable plaques (VP). However, we have interest to know if ELMPs contain Mp lipoprotein antigens and if they are related to oxLDL and plaque vulnerability. Methods: We studied three groups of coronary arteries: VP (vulnerable plaque; n=13), stable plaques (SP; n=7), and normal arteries (NA; n=7). All cases were studied by immuno electron microscopy, and the mean numbers of ELMPs, oxLDL and Mp antigens, inside and outside ELMP, were obtained. Double colloidal immunogold particles (anti-oxLDL and anti-Mp) allowed the simultaneous localization of both antigens. Results: There was a significant higher amount of ELMPs in VP, with positive dots for both oxLDL and Mp antigens inside them, compared to other two groups (p<0.01). Mp and oxLDL antigens were co-localized in lipidic nanoparticles intra ELMPs, showing positive correlation (r=0.60; P=0.04). High amount of oxLDL and Mp antigens extra ELMPs were seen in VP, but not in stable plaques. Conclusion: Plaque vulnerability in atherosclerosis may be related to presence of ELMPs, containing M. pneumoniae lipoproteins and oxLDL. We hypothesized that M. pneumoniae lipoproteins oxidation could be a mechanism for this association. However, further data are necessary to prove this hypothesis.

Palavras-chave

Atherosclerosis, Microparticle, Infection, Vulnerable plaque

URI

https://observatorio.fm.usp.br/handle/OPI/24225

Referências

Allen LAH, 2007, CELL MICROBIOL, V9, P817, DOI 10.1111/j.1462-5822.2007.00906.x
Baron M, 2012, J CELL MOL MED, V16, P1365, DOI 10.1111/j.1582-4934.2011.01486.x
Bezerra HG, 2001, CARDIOVASC PATHOL, V10, P189, DOI 10.1016/S1054-8807(01)00070-9
Campos EG, 2005, GENET MOL RES, V4, P409
DUARTE MIS, 1992, ULTRASTRUCT PATHOL, V16, P475
Hanage WP, 2014, NATURE, V512, P247, DOI 10.1038/512247a
Higuchi Maria de Lourdes, 2003, Arq. Bras. Cardiol., V81, P12, DOI 10.1590/S0066-782X2003000900001
Higuchi Maria L, 2006, Clinics, V61, P473, DOI 10.1590/S1807-59322006000500016
Higuchi ML, 2004, IMMUNOLOGY 2004: CYTOKINE NETWORK, REGULATORY CELLS, SIGNALING, AND APOPTOSIS, APPENDIX, P89
Homma Yasuhiko, 2004, J Atheroscler Thromb, V11, P265
Karlsson F, 2013, DIABETES, V62, P3341, DOI 10.2337/db13-0844
Kockx MM, 1998, ARTERIOSCL THROM VAS, V18, P1519
Leroyer AS, 2007, J AM COLL CARDIOL, V49, P772, DOI 10.1016/j.jacc.2006.10.053
Lu YG, 2013, INT J CARDIOL, V168, P5396, DOI 10.1016/j.ijcard.2013.08.050
Mallat Z, 1999, CIRCULATION, V99, P348
Momiyama Y, 2004, ATHEROSCLEROSIS, V176, P139, DOI 10.1016/j.atherosclerosis.2004.04.019
Pekkala S, 2014, J DIABETES METAB, V6, P480
Peluso Ilaria, 2012, Endocrine Metabolic & Immune Disorders-Drug Targets, V12, P351
Ravnskov U, 2009, ANN CLIN LAB SCI, V39, P3
Rosenfeld ME, 2013, CURR OPIN PHARMACOL, V13, P154, DOI 10.1016/j.coph.2013.01.003
Rosenfeld ME, 2011, THROMB HAEMOSTASIS, V106, P858, DOI 10.1160/TH11-06-0392
Suades R, 2013, THROMB HAEMOSTASIS, V110, P366, DOI 10.1160/TH13-03-0238
Suades R, 2012, THROMB HAEMOSTASIS, V108, P1208, DOI 10.1160/TH12-07-0486
Tesselaar MET, 2009, J THROMB HAEMOST, V7, P1421, DOI 10.1111/j.1538-7836.2009.03504.x
Yasim A, 2010, AM J MED SCI, V339, P448, DOI 10.1097/MAJ.0b013e3181d4eb71

Coleções

Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor

Página do item completo